194 related articles for article (PubMed ID: 29773230)
1. Medications received by patients with juvenile dermatomyositis.
Kishi T; Bayat N; Ward MM; Huber AM; Wu L; Mamyrova G; Targoff IN; Warren-Hicks WJ; Miller FW; Rider LG;
Semin Arthritis Rheum; 2018 Dec; 48(3):513-522. PubMed ID: 29773230
[TBL] [Abstract][Full Text] [Related]
2. The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.
Giancane G; Lavarello C; Pistorio A; Oliveira SK; Zulian F; Cuttica R; Fischbach M; Magnusson B; Pastore S; Marini R; Martino S; Pagnier A; Soler C; Staņēvicha V; Ten Cate R; Uziel Y; Vojinovic J; Fueri E; Ravelli A; Martini A; Ruperto N;
Pediatr Rheumatol Online J; 2019 May; 17(1):24. PubMed ID: 31118099
[TBL] [Abstract][Full Text] [Related]
3. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis.
Mamyrova G; Kishi T; Targoff IN; Ehrlich A; Curiel RV; Rider LG;
Rheumatology (Oxford); 2018 Nov; 57(11):1956-1963. PubMed ID: 30016492
[TBL] [Abstract][Full Text] [Related]
4. Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis.
Lang B; Dooley J
J Pediatr; 1996 Mar; 128(3):429-32. PubMed ID: 8774518
[TBL] [Abstract][Full Text] [Related]
5. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
6. Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis.
Lanis A; Volochayev R; Kleiner DE; Vittal A; Heller T; Rider LG; Shenoi S
Pediatr Rheumatol Online J; 2022 Apr; 20(1):30. PubMed ID: 35443665
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate.
Al-Mayouf S; Al-Mazyed A; Bahabri S
Clin Rheumatol; 2000; 19(2):138-41. PubMed ID: 10791626
[TBL] [Abstract][Full Text] [Related]
8. Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis.
Kim NN; Lio PA; Morgan GA; Jarvis JN; Pachman LM
Arch Dermatol; 2011 Jul; 147(7):831-5. PubMed ID: 21422326
[TBL] [Abstract][Full Text] [Related]
9. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis.
Gunawardena H; Wedderburn LR; North J; Betteridge Z; Dunphy J; Chinoy H; Davidson JE; Cooper RG; McHugh NJ;
Rheumatology (Oxford); 2008 Mar; 47(3):324-8. PubMed ID: 18238791
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis.
de Inocencio J; Enríquez-Merayo E; Casado R; González-Granado LI
Pediatrics; 2016 Apr; 137(4):. PubMed ID: 26966131
[TBL] [Abstract][Full Text] [Related]
11. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.
Rider LG; Katz JD; Jones OY
Rheum Dis Clin North Am; 2013 Nov; 39(4):877-904. PubMed ID: 24182859
[TBL] [Abstract][Full Text] [Related]
12. Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis.
Yu HH; Chang HM; Chiu CJ; Yang YH; Lee JH; Wang LC; Lin YT; Chiang BL
J Microbiol Immunol Infect; 2016 Apr; 49(2):264-70. PubMed ID: 25070283
[TBL] [Abstract][Full Text] [Related]
13. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.
Ruperto N; Pistorio A; Oliveira S; Zulian F; Cuttica R; Ravelli A; Fischbach M; Magnusson B; Sterba G; Avcin T; Brochard K; Corona F; Dressler F; Gerloni V; Apaz MT; Bracaglia C; Cespedes-Cruz A; Cimaz R; Couillault G; Joos R; Quartier P; Russo R; Tardieu M; Wulffraat N; Bica B; Dolezalova P; Ferriani V; Flato B; Bernard-Medina AG; Herlin T; Trachana M; Meini A; Allain-Launay E; Pilkington C; Vargova V; Wouters C; Angioloni S; Martini A;
Lancet; 2016 Feb; 387(10019):671-678. PubMed ID: 26645190
[TBL] [Abstract][Full Text] [Related]
14. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
[TBL] [Abstract][Full Text] [Related]
15. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
16. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
Walling HW; Gerami P; Sontheimer RD
Paediatr Drugs; 2010; 12(1):23-34. PubMed ID: 20034339
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature.
Xu Y; Ma X; Zhou Z; Li J; Hou J; Zhu J; Kang M; Lai J; Li X
Pediatr Rheumatol Online J; 2021 Jan; 19(1):2. PubMed ID: 33407602
[TBL] [Abstract][Full Text] [Related]
18. Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis.
Karasawa R; Yudoh K; Sato T; Tanaka M; Tamaki M; Sabbagh SE; O'Hanlon TP; Noroozi-Farhadi P; Targoff IN; Flegel WA; Mammen AL; Miller FW; Hicar MD; Rider LG; Jarvis JN
Rheumatology (Oxford); 2022 Jul; 61(7):2969-2977. PubMed ID: 34791087
[TBL] [Abstract][Full Text] [Related]
19. Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists.
Hinze CH; Speth F; Oommen PT; Haas JP
Pediatr Rheumatol Online J; 2018 Jun; 16(1):38. PubMed ID: 29925381
[TBL] [Abstract][Full Text] [Related]
20. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.
Wu JQ; Lu MP; Reed AM
World J Pediatr; 2020 Feb; 16(1):31-43. PubMed ID: 31556011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
